Omeros
OMEROmeros Corporation is a commercial-stage biotechnology company focused on discovering and developing first-in-class protein and small-molecule therapeutics for large-market and orphan indications.
Earnings
Next report
Nov 12, 2026 (in 2 months)Financials
Q2 2026Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Omeros Corporation is a commercial-stage biotechnology company focused on discovering and developing first-in-class protein and small-molecule therapeutics for large-market and orphan indications. The company specializes in treating complement-mediated diseases, cancers, and addictive or compulsive disorders by targeting specific immune system pathways. Its core value proposition lies in its leadership in complement science, particularly the lectin and alternative pathways, to address significant unmet medical needs.
Omeros is a pioneer in lectin pathway inhibition, holding the first FDA-approved therapy for TA-TMA and maintaining a significant patent estate in complement science.
FAQ
- What is Omeros's market cap?
- Omeros (OMER) has a market capitalization of $1.3B and trades on NASDAQ.
- What is Omeros's revenue and profitability?
- Omeros generated $97.2M in trailing twelve-month revenue with net income of $13.0M, representing a net margin of -136.6%. Gross margin stands at 98.9%. The latest reported period is Q2 2026.
- Who are Omeros's competitors?
- Omeros's key competitors include Citius Oncology, Inc. Common Stock, Immunome, Inc., Dianthus Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Omeros partner with?
- Omeros's notable partners include Novo Nordisk Healthcare AG, Lonza Biologics Tuas Pte. Ltd., Vetter Pharma International, GmbH, and others.
- Where is Omeros headquartered?
- Omeros is headquartered in United States of America and employs approximately 198 people. It has been publicly traded since 2009.
